- Home
- LUNG vs NRXP Comparison
LUNG vs NRXP Comparison
Compare LUNG & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUNG | NRXP |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 63.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LUNG | NRXP |
|---|---|---|
| Price | $2.22 | $2.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $6.81 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 986.2K | 519.3K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $91,664,000.00 | $242,000.00 |
| Revenue This Year | $9.21 | N/A |
| Revenue Next Year | $5.03 | $821.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.59 | N/A |
| 52 Week Low | $1.31 | $1.41 |
| 52 Week High | $9.37 | $6.01 |
Technical Indicators
Market Signals| Indicator | LUNG | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 56.82 |
| Support Level | $2.16 | $1.96 |
| Resistance Level | $2.65 | $2.52 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 36.43 | 93.55 |
Price Performance
Historical ComparisonAbout LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.